Denali-Sanofi's ALS drug fails to meet mid-stage trial goal

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 16, 2024 at 11:52: AM
via Drug developer Denali Therapeutics (DNLI.O) said on Friday its and partner Sanofi's (SASY.PA) experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage study.

article source
 

<



Similar threads

cafead
Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and...
Replies
0
Views
108
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Denali Moving Forward with Sanofi-Partnered ALS Candidate
Replies
0
Views
96
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different...
Replies
0
Views
265
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi Pledges $125M to Denali in Pact for Neuro, Inflammation Drugs
Replies
0
Views
174
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics
Replies
0
Views
212
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote